SurroMed, Japanese Genomics Firm to Develop, Sell Biomarkers

Jul 31, 2003

NEW YORK, July 31 - SurroMed and Japanese genomics service company MediBic will co-develop biomarkers for drug discovery, the companies said today.

Registering provides access to this and other free content.

Already have an account?
Login Now.

Breaking News

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.